Boston Scientific Aktie
| 90,36USD | -0,07USD | -0,08% |
WKN: 884113 / ISIN: US1011371077
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,58 |
| The Vanguard Group, Inc. | 8,52 |
| Vanguard Group, Inc. (Subfiler) | 8,47 |
| Fidelity Management & Research Co. LLC | 7,36 |
| State Street Corp. | 4,27 |
| Massachusetts Financial Services Co. | 3,88 |
| Vanguard Total Stock Market ETF | 3,16 |
| Vanguard 500 Index Fund | 2,65 |
| PRIMECAP Management Co. | 2,57 |
| BlackRock Fund Advisors | 2,49 |
| BlackRock Institutional Trust Co. NA | 2,22 |
| Wellington Management Co. LLP (Wellington Breakout) | 2,03 |
| Geode Capital Management LLC | 2,01 |
| Massachusetts Financial Services Co. | 1,74 |
| Vanguard PRIMECAP Fund | 1,74 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 36 000 | 38 000 | 41 000 | 45 000 | 48 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,30 | 0,26 | 0,29 | 0,28 | 0,30 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4 699 | 6 694 | 6 317 | 5 760 | 6 514 |
| Summe Anlagevermögen | 25 866 | 24 083 | 25 912 | 26 709 | 28 622 |
| Summe Aktiva | 30 565 | 30 777 | 32 229 | 32 469 | 35 136 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 10 351 | 9 614 | 9 525 | 9 282 | 9 492 |
| Summe Fremdkapital | 16 688 | 15 450 | 15 607 | 14 896 | 15 606 |
| Summe Eigenkapital | 13 877 | 15 327 | 16 622 | 17 573 | 19 530 |
| Summe Passiva | 30 565 | 30 777 | 32 229 | 32 469 | 35 136 |
Adresse
| 300 Boston Scientific Way, 01752-1234 Marlborough | |
| Telefon | +1 (508) 683-4000 |
| Internet | http://www.bostonscientific.com |
Management
|
Arthur Crosswell Butcher
EVP, Group President-MedSurg & Asia Pacific |
|
Brenda Becker
Senior Vice President-Global Government Affairs |
|
Charles J. Dockendorff
Independent Director |
|
Charlie Attlan
SVP-New Business Development, Strategy & Portfolio |
|
Cheryl Pegus
Director |
|
Colin Morrison
Director-Business Development & Venture Capital |
|
Daniel J. Brennan
Chief Financial Officer & Executive Vice President |
|
David C. Habiger
Director |
|
David Scott Wichmann
Independent Director |
|
Edward J. Ludwig
Lead Independent Director |
|
Ellen M. Zane
Independent Director |
|
Emily Woodworth
Chief Accounting Officer, SVP & Group Controller |
|
Eric Francis Yves Thepaut
EVP, President-Europe, Middle East & Africa |
|
Jeffrey B. Mirviss
SVP & President-Peripheral Interventions |
|
Jessica L. Mega
Independent Director |
|
Jim Cassidy
Vice President & Franchise Lead-Pain Management |
|
Jodi Eddy
Chief Information & Digital Officer, Senior VP |
|
John Bradley Sorenson
Executive Vice President-Global Operations |
|
John Edward Sununu
Independent Director |
|
Jonathan Richard Monson
Senior Vice President-Investor Relations |
|
Joseph M. Fitzgerald
President-Interventional Cardiology & Executive VP |
|
June Chang
President-Greater China |
|
Kathryn Graves Unger
Vice President-Environmental, Social & Governance |
|
Kenneth Stein
Global Chief Medical Officer & Senior VP |
|
Lauren Tengler
Head-Investor Relations |
|
Mark Bickel
VP-Finance & Global Controller-Rhythm Management |
|
Mary Beth Moynihan
Chief Marketing Officer & Senior VP-Market Access |
|
Meghan M. Scanlon
SVP & President-Urology & Pelvic Health Division |
|
Michael F. Mahoney
Chairman, President & Chief Executive Officer |
|
Michael Jones
Senior Vice President & President-Endoscopy |
|
Milad Girgis
Vice President & Franchise Lead |
|
Rosaleen Burke
Senior Vice President-Global Quality & Regulatory |
|
Samuel Conaway
President-US Sales Cardiology Group |
|
Susan E. Morano
Independent Director |
|
Susan J. Thompson
Chief Corporate Counsel, VP & Assistant Secretary |
|
Vance Ronald Brown
Secretary, Senior Vice President & General Counsel |
|
Wendy Carruthers
Executive Vice President-Human Resources |
|
Yoshiaki Fujimori
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
